皮林促进非小细胞肺癌的进展,通过增加ODC1抑制自
Yan-Ping Li1, Zi-Jia Huang2, Quan-Kuo He3
1Research Laboratory of Zhuang & Yao Medicine, Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530201, China.
Journal of proteome research
|April 22, 2024
概括
皮林和奥尼丁脱碳酶1 (ODC1) 被确定为非小细胞肺癌 (NSCLC) 的新预后生物标志物. 针对皮林/ODC1/自途径可能为NSCLC患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 病原体需要进一步调查.
- 自是一种细胞降解过程,在癌症中经常有失调.
- 在NSCLC中迫切需要新的自调节剂.
研究的目的:
- 确定NSCLC中的新型自相关调节体.
- 调查皮林和甲素脱碳酶1 (ODC1) 在NSCLC进展中的作用.
- 探索皮林/ODC1/自轴作为潜在的治疗点.
主要方法:
- 定量蛋白质组学 (数据独立获取) 用于识别差异表达蛋白质.
- 细胞增殖试验和自抑制研究.
- 免疫组织化学评估NSCLC组织中的蛋白质表达.
主要成果:
- 皮林表达在NSCLC上调,与预后不佳相关.
- 皮林过度表达抑制了自并促进了NSCLC的扩散.
- ODC1由皮林调节,其耗尽可以逆转皮林诱导的影响.
- 高皮林和ODC1表达表明NSCLC患者的风险更高.
结论:
- 皮林和ODC1被确定为NSCLC的新型预后生物标志物.
- 皮林/ODC1/自轴在NSCLC瘤发生过程中发挥着重要作用.
- 针对这种途径为NSCLC提供了潜在的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


